Precision medicine enhances prostate cancer treatment with genetic profiling

Men with metastatic castration-resistant prostate cancer should be treated primarily with second-generation hormone drugs, which offer better treatment response and longer life expectancy than chemotherapy.

Neurocrine axes Takeda-partnered depression program, switches focus for seizure drug after PhII failures

Neurocrine Biosciences has been hit with a pair of mid-stage failures for its partnered candidates in major depressive disorder (MDD) and focal onset seizures (FOS),

November 11, 2023

New Generative AI App Measures Vital Signs Through A Selfie

What You Should Know: Dr. Renee Dua and Nick Desai — who previously founded and built visionary doctor house call company Heal — today introduced Together by

June 20, 2023

The VPAS fallout continues – Celltrion pulls high-profile biosimilar from UK market – Pharmaceutical Technology

Celltrion had voiced initial worries about the likely unsustainability of the 2023 VPAS rate long before it was set last December. Credit: Pavel Kapysh /

July 3, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.